GLP-1: from the lab to your plateHow to harness your own “Ozempic hormone” without injections

You’ve probably heard names like Ozempic, Wegovy, Mounjaro, Zepbound.
All of them are based on a hormone your own gut produces: GLP-1.

The question I hear almost every day in clinic is:

“Doctor, if my body already makes GLP-1, can I stimulate it naturally to lose weight, even if I don’t have access to the injections?”

The short answer is yes… but with some nuances.

Before we get to the practical part, I want to walk you through the story of this hormone as a kind of timeline—just a conversation between you and me.

The story of GLP-1, told as a timeline

More than 100 years ago

Scientists discover that the intestine doesn’t just digest food; it also acts as an endocrine gland. Hormones like secretinare identified in the classic experiments of Bayliss and Starling. Little by little, we begin to suspect that the gut “talks” to the pancreas to help regulate blood sugar.

Decades later

With better lab techniques, researchers notice something curious: when we drink glucose, the pancreas releases more insulin than when the same amount of glucose is given through a vein.

This gives rise to the concept of the “incretin effect”: the intestine boosts the insulin response when nutrients come through the digestive tract.

1970s – the first messenger: GIP

John Brown isolates the first incretin, GIP (glucose-dependent insulinotropic peptide), from porcine gastric extracts. It’s the first big step toward understanding how the gut helps control glucose.

1980s – GLP-1 appears

Researchers clone the glucagon gene and discover that from a large precursor, proglucagon, several peptides are produced thanks to very specific enzymatic “scissors” (prohormone convertases) that cut in precise places.

From that processing, GLP-1 is born—another powerful incretin.

In those years, studies show that GLP-1:

• Increases insulin secretion only when glucose is present
• Lowers glucagon
• Helps reduce blood glucose in animals and humans

At the same time, a key idea is confirmed: many hormones are produced as big prohormones and then trimmed into their active pieces. That’s true for insulin, parathyroid hormone, glucagon, and GLP-1.

1990s and 2000s – from “curious hormone” to real treatment

Scientists identify GLP-1 receptors and begin developing GLP-1 receptor agonists (GLP-1RAs)—molecules that imitate GLP-1 but last much longer in the bloodstream.

A pharmaceutical company develops the first GLP-1RA for type 2 diabetes. What starts as a glucose-lowering therapy becomes something bigger: patients lose weight, feel less hungry, and see their cardiovascular risk improve.

In parallel, GLP-2 is discovered, another peptide derived from proglucagon that stimulates intestinal mucosal growth. Today it’s used to treat short bowel syndrome.

From 2016 onward – the heart steps into the picture

Large cardiovascular outcome trials arrive. They show that long-acting GLP-1RAs reduce heart attack, stroke, cardiovascular death, and all-cause mortality in people with type 2 diabetes. Later, benefits are seen in people with obesity and in some with heart failure with preserved ejection fraction.

Today – the “GLP-1 revolution”

GLP-1RAs become protagonists in treating type 2 diabetes and obesity. But price and access remain major barriers.

In November 2025, the White House announced deals with Eli Lilly and Novo Nordisk to significantly cut the prices of Ozempic, Wegovy, Mounjaro, and Zepbound—both for patients buying through the TrumpRx platform and for many people on Medicare and Medicaid.The White House+2www.asge.org+2

According to these agreements, list prices above $1,000 per month would, in many cases, drop to around $245–350 per month, with copays near $50 for some Medicare beneficiaries.The White House+2www.asge.org+2

If all of this is implemented as announced, millions more people could gain access. Even so, everyday reality is that:

• Not all insurance plans cover these drugs
• Strict criteria around BMI and comorbidities are often required
• Availability varies by country, insurance, and financial situation

That’s why so many patients ask how they can leverage their own GLP-1 when these therapies aren’t an option.

A detailed discussion of each medication, dose, trial, and side effect would go beyond this article. Here we’ll focus on the basics—and especially on what you can start doing today.

What GLP-1 does in your body

GLP-1 is produced by L-cells in your intestine, mainly in the ileum and colon, when you eat.

Its main functions:

• Increases insulin secretion when glucose goes up
• Decreases glucagon, reducing the liver’s glucose output
• Slows gastric emptying, so you feel full sooner and stay full longer
• Acts in the brain to lower appetite

Your natural GLP-1 goes up about 2–4 times after a meal, for 1–2 hours, and then drops quickly because it’s broken down in minutes.

GLP-1 medications, on the other hand, keep the receptor activated in a sustained way, for days—or even a full week.

GLP-1 drugs vs. natural GLP-1: being honest about expectations

As a family and lifestyle medicine physician, I have to speak plainly with you.

The evidence is clear: stimulating your own GLP-1 through diet and lifestyle does not reach the levels or metabolic effects of GLP-1 agonist medications. Drugs like semaglutide and tirzepatide are engineered to resist rapid breakdown of native GLP-1 and maintain sustained receptor activation and clinical effects that we simply can’t achieve by “natural” stimulation alone.

What the medications can do

GLP-1 receptor agonists:

• Activate the GLP-1 receptor continuously, at levels above normal physiology
• Lead to average weight loss of about 10–20% of initial body weight in well-run clinical trials
• Strongly improve blood glucose, blood pressure, lipid profile, and cardiovascular risk

In return, they:

• Increase the risk of digestive side effects (nausea, vomiting, diarrhea, constipation)
• Raise the risk of gallbladder issues
• And, more rarely, may be associated with other serious events that require monitoring

What we can achieve with lifestyle and natural GLP-1

With an intensive program focused on healthy eating, physical activity, restorative sleep, stress management, and behavioral support, evidence shows that most people can lose about 5–10% of their starting weight over 6–12 months.

That’s not “little.” That level of loss already improves glucose, blood pressure, and lipids.

What studies show:

• Intensive lifestyle programs often achieve around 5–7% weight loss in a year
• Losses above 10% are possible, but less common without medication or surgery
• Natural GLP-1 plays a role, but its increase is modest compared with a GLP-1RA

So:

• Lifestyle is the foundation and is highly effective for your overall health
• But it doesn’t replace GLP-1RAs when very large weight loss or very tight glucose control is needed

Even so, for many people who cannot or do not want to use these drugs, working with natural GLP-1 is still a powerful and safe way to improve health and weight.

Is the “natural” approach safer?

In general, yes.

Changes in diet and lifestyle have a very favorable safety profile:

• Side effects are usually mild: some digestive discomfort when increasing fiber, or fatigue if exercise is too intense at the start
• Serious complications are rare when the plan is well designed and supervised

GLP-1RAs, while offering major metabolic and cardiovascular benefits, do bring:

• More digestive side effects
• Higher risk of gallbladder disease
• The need for ongoing medical monitoring

That’s why, even when we use GLP-1RAs, I always insist: lifestyle is the “ground” on which treatment stands.

So… can we increase natural GLP-1?

Yes, we can stimulate your own GLP-1 with:

• A plant-forward, whole-food diet, rich in fiber
• Healthy fats (mono- and polyunsaturated)
• Adequate protein
• Structured meals and a regular eating rhythm
• Regular physical activity
• Quality sleep and stress management

What we cannot do is turn your gut into a GLP-1 “pump” comparable to a weekly injection. The magnitude and duration of the effect will be smaller.

But that does not mean it’s not worth it. It absolutely is.

A practical plan to boost GLP-1 naturally

I want to give you a clear, realistic guide. Not a perfect diet—just sustainable changes.

1. Eat more fiber and resistant starch

Fiber from:

• Legumes: beans, lentils, chickpeas
• Vegetables: especially leafy greens, cruciferous vegetables, carrots, squash
• Whole fruits (not juices): apples, pears, berries, citrus
• Whole grains: oats, quinoa, brown rice, true 100% whole-wheat bread

…ferments in the colon and produces short-chain fatty acids. These stimulate the L-cells to release more GLP-1 and improve insulin sensitivity.

Practical tips:

• Include legumes at least 3–4 times per week
• Fill half your plate with vegetables at lunch and dinner
• Always choose whole grains over refined

2. Prefer healthy fats (not a “high-fat diet”)

Mono- and polyunsaturated fats, in moderate amounts, increase GLP-1 after meals:

• Extra-virgin olive oil
• Nuts: walnuts, almonds, pistachios
• Seeds: chia, flaxseed, sesame
• Fatty fish: salmon, sardines, mackerel

I want to be very clear:
I do not recommend a chronically high-fat diet as a GLP-1 strategy. In the long run—especially if saturated fats predominate—it increases cardiovascular risk, favors inflammation, and may even harm the cells that produce GLP-1.

The key is:

• Prioritize unsaturated fats
• Keep an overall balanced, plant-forward, Mediterranean-style pattern
• Avoid excess calories

3. Make sure you get quality protein in every meal

Protein and some specific amino acids can stimulate GLP-1 secretion and help you feel full.

Good sources:

• Legumes
• Fish
• Skinless chicken or turkey
• Eggs
• Low-fat or fermented dairy, if you tolerate it
• Tofu, tempeh, textured soy

Try to include a palm-sized portion of protein in each main meal.

4. Use the “bioactives” in plants

Many plant compounds modulate GLP-1 and metabolism:

• Quercetin: apples, onions, grapes
• Catechins: green tea
• Curcumin: turmeric
• Capsaicin: chili peppers
• Resveratrol: berries, purple grapes
• Spices like cinnamon and ginger

You don’t need expensive supplements. It’s enough to:

• Use herbs and spices daily
• Drink green tea if it’s not contraindicated for you
• Eat a wide variety of colorful fruits and vegetables

5. Structure your meals to help GLP-1 work with you

Small changes in order and rhythm can matter:

• Front-load your day: “Breakfast like a king, lunch like a prince, dine like a pauper.”
  A breakfast rich in protein, fiber, and some healthy fat helps control hunger later.
• Eat carbs last: start your meal with vegetables and protein, then add whole-grain carbs.
  This smooths glucose spikes and supports a more orderly GLP-1–insulin response.
• Eat slowly and without rush: GLP-1 takes time to rise. If you eat very fast, your brain gets the satiety signal too late and you overeat.
• Consider a 12–16-hour overnight fast between dinner and breakfast, if it’s safe for you.
  This can improve insulin sensitivity and help regulate appetite.

6. What TO do for weight loss

This is what I usually work on with patients:

• Accumulate at least 150 minutes per week of exercise that raises your heart rate.
  For weight maintenance and sometimes for more loss, aim toward 200–300 minutes.
• Move as much as you can: take the stairs, walk more, stand up frequently.
• Eliminate caloric drinks: sodas, juices, sweetened coffees, sugary milks.
• Avoid alcohol or keep it to a minimum.
• Swap refined grains for whole ones: real whole-grain bread, brown or parboiled rice, al dente pasta, quinoa.
• Avoid ultra-processed foods and fast food.
• Make vegetables the visual base of your plate.
• Increase fiber-rich foods: veggies, whole fruits, legumes, nuts, seeds.
• Watch portions—especially starches, fats, and desserts.
• Eat dinner early and light.
• Drink about 6–8 glasses of water daily, unless your doctor gives you other instructions.
• Keep meal times relatively consistent.
• Allow small, planned treats in controlled portions so your plan is sustainable.

7. What NOT to do

• Don’t punish yourself or starve. Extreme restriction almost always leads to rebound.
• Don’t skip meals in a chaotic way.
• Don’t cut out entire food groups (like all carbohydrates) without a clear medical reason and supervision.
• Don’t base your diet chronically on shakes, bars, or meal replacements.
• Don’t replace sugar with huge amounts of non-caloric sweeteners thinking you’re “tricking” your body—they tend to keep sweet cravings alive.
• Don’t keep in your house the foods you know are hardest for you to control.
• Don’t eat distracted in front of screens or while driving.
  Sit down, eat calmly, and be present.
• Don’t aim for ultra-rapid weight loss or unrealistic goals.
• Don’t assume one slip erases all your progress.
  If you go off plan for a day, simply get back on track at the next meal.

Other lifestyle pillars that also shape your appetite

GLP-1 doesn’t live alone. It shares the stage with many other hunger and satiety hormones. That’s where the rest of lifestyle medicine pillars come in:

• Sleep: sleeping less than 7 hours disrupts appetite control, raises ghrelin (the hunger hormone), and makes weight loss harder.
• Stress: high cortisol pushes you toward ultra-processed foods and promotes abdominal fat storage.
  Breathing exercises, meditation, prayer, nature walks, or activities you enjoy help regulate it.
• Risky substances: alcohol and tobacco worsen metabolic control and add empty calories or vascular damage.
• Social connection: eating with others and having support from family, friends, or group programs greatly improves long-term adherence.

How much weight can you realistically expect to lose with lifestyle alone?

With a serious, structured, and supported program, most people can:

• Lose about 5–10% of their starting weight over 6–12 months
• Keep a meaningful portion of that loss if they maintain habits and stay supported

Larger losses are possible, but less common without medications or surgery. And even though we often focus on the scale, metabolic health improvements start as early as 5% weight loss.

A final message, from doctor to patient

I want you to remember three ideas:

1. Your body already produces GLP-1.
   We can stimulate it with a plant-forward, whole-food diet, fiber, healthy fats, adequate protein, movement, good sleep, and stress management.
2. GLP-1RAs are powerful tools with huge benefits in diabetes, obesity, and cardiovascular risk, but they’re not risk-free and not always accessible.
3. Lifestyle is never “little.”
   Even if its effect on GLP-1 doesn’t reach pharmacological levels, its overall impact on your health is deep and long-lasting.

This article is for education. It doesn’t replace a medical visit.
Your comorbidities, medications, cardiovascular situation, and personal conditions matter. Always discuss major changes in diet, exercise, or treatment with your health care team.

My goal is to walk with you—with knowledge, honesty, and hope.
You bring your body and your willingness. I bring the science and the plan.

Step by step, we can help your own biology work more in your favor.

🌍 This article is also available in Spanish. Please use the language switcher in the top menu.

Glossary of terms and abbreviations

GLP-1
Glucagon-Like Peptide-1 / Péptido similar al glucagón tipo 1
Hormone produced in the gut that increases insulin, reduces glucagon, lowers appetite, and slows gastric emptying.

GLP-1RA
GLP-1 Receptor Agonists / Agonistas del receptor de GLP-1
Drugs that mimic and amplify the action of natural GLP-1, used for type 2 diabetes and obesity (e.g., semaglutide, tirzepatide).

GIP
Glucose-dependent Insulinotropic Peptide / Péptido insulinotrópico dependiente de glucosa
The first incretin discovered; it also stimulates insulin secretion.

Incretin
Intestinal hormone that increases insulin secretion when we eat. The main incretins are GIP and GLP-1.

Proglucagon
A large precursor molecule that gives rise to several peptides—including GLP-1, GLP-2, and glucagon—after being “cut” by specific enzymes.

GLP-2
Hormone derived from proglucagon that stimulates growth and repair of the intestinal mucosa. Used in short bowel syndrome.

GLP-1 receptor
The cellular structure where GLP-1 (or its agonists) act to generate effects on insulin, glucose, and appetite.

Ozempic®
Brand name for semaglutide used in type 2 diabetes.

Wegovy®
Higher-dose semaglutide approved for obesity treatment.

Mounjaro®
Brand name for tirzepatide, a dual GLP-1 and GIP agonist for type 2 diabetes.

Zepbound®
Tirzepatide approved for obesity treatment.

BMI
Body Mass Index (Índice de Masa Corporal)
Measure relating weight and height, used to define overweight, obesity, and eligibility for some treatments.

Gastric emptying
Time it takes for the stomach to send food into the intestine. GLP-1 delays this, supporting satiety.

Incretin effect
Phenomenon by which glucose taken by mouth triggers more insulin release than the same glucose given intravenously.

L-cells
Intestinal cells (mostly in ileum and colon) that produce GLP-1 and GLP-2 in response to food.

Gastrointestinal adverse effects
Digestive symptoms common with GLP-1RAs (nausea, vomiting, diarrhea, constipation).

Short-chain fatty acids (SCFAs / AGCC)
Molecules produced by fiber fermentation in the colon. They stimulate GLP-1 and improve insulin sensitivity.

TrumpRx
Platform announced by the U.S. government to offer certain medications— including GLP-1 drugs—at reduced prices for cash-paying patients and to support Most-Favored-Nation pricing agreements.The White House+2AMCP+2

Medicare / Medicaid
Public health insurance in the U.S.:

• Medicare: for adults 65+ and some people with disabilities
• Medicaid: for people with low income

Sources

Hira T, Trakooncharoenvit A, Taguchi H, Hara H.Hira T, Trakooncharoenvit A, Taguchi H, Hara H. Improvement of glucose tolerance by food factors having glucagon-like peptide-1 releasing activity. Int J Mol Sci. 2021;22(12):6623. doi:10.3390/ijms22126623.

Holst JJ, Jepsen SL, Modvig I. GLP-1: Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy. Curr Opin Pharmacol. 2022;63:102189. doi:10.1016/j.coph.2022.102189.

Jakicic JM, Apovian CM, Barr-Anderson DJ, et al. Physical activity and excess body weight and adiposity for adults. American College of Sports Medicine consensus statement. Med Sci Sports Exerc. 2024;56(10):2076-2091. doi:10.1249/MSS.0000000000003520.

Briere DA, Bueno AB, Gunn EJ, Michael MD, Sloop KW. Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery. Diabetes. 2018;67(2):309-320. doi:10.2337/db17-0607.

Tanday N, Flatt PR, Irwin N. Amplifying the antidiabetic actions of glucagon-like peptide-1: Potential benefits of new adjunct therapies. Diabet Med. 2021;38(12):e14699. doi:10.1111/dme.14699.

Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225. doi:10.1053/j.gastro.2022.08.045.

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034.

Moiz A, Filion KB, Toutounchi H, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials. Ann Intern Med. 2025;178(2):199-217. doi:10.7326/ANNALS-24-01590.

Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: A review. JAMA.2023;330(20):2000-2015. doi:10.1001/jama.2023.19897.

Xie Z, Zheng G, Liang Z, et al. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: An updated systematic review and network meta-analysis of randomized controlled trials. Metabolism. 2024;161:156038. doi:10.1016/j.metabol.2024.156038.

Wong HJ, Sim B, Teo YH, et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: A systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care. 2025;48(2):292-300. doi:10.2337/dc24-1678.

Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the ACLM, ASN, OMA, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.

FDA Orange Book. U.S. Food and Drug Administration. Accessed 2024–2025. (No doi; regulatory database.)Int J Mol Sci. 2021;22(12):6623. doi:10.3390/ijms22126623.

Holst JJ, Jepsen SL, Modvig I. GLP-1: Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy. Curr Opin Pharmacol. 2022;63:102189. doi:10.1016/j.coph.2022.102189.

Jakicic JM, Apovian CM, Barr-Anderson DJ, et al. Physical activity and excess body weight and adiposity for adults. American College of Sports Medicine consensus statement. Med Sci Sports Exerc. 2024;56(10):2076-2091. doi:10.1249/MSS.0000000000003520.

Briere DA, Bueno AB, Gunn EJ, Michael MD, Sloop KW. Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery. Diabetes. 2018;67(2):309-320. doi:10.2337/db17-0607.

Tanday N, Flatt PR, Irwin N. Amplifying the antidiabetic actions of glucagon-like peptide-1: Potential benefits of new adjunct therapies. Diabet Med. 2021;38(12):e14699. doi:10.1111/dme.14699.

Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225. doi:10.1053/j.gastro.2022.08.045.

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034.

Moiz A, Filion KB, Toutounchi H, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials. Ann Intern Med. 2025;178(2):199-217. doi:10.7326/ANNALS-24-01590.

Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: A review. JAMA.2023;330(20):2000-2015. doi:10.1001/jama.2023.19897.

Xie Z, Zheng G, Liang Z, et al. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: An updated systematic review and network meta-analysis of randomized controlled trials. Metabolism. 2024;161:156038. doi:10.1016/j.metabol.2024.156038.

Wong HJ, Sim B, Teo YH, et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: A systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care. 2025;48(2):292-300. doi:10.2337/dc24-1678.

Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the ACLM, ASN, OMA, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.

FDA Orange Book. U.S. Food and Drug Administration. Accessed 2024–2025. (No doi; regulatory database.)